Article

Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIV

2025-08-28

Abstract excerpt

Oral pre-exposure prophylaxis (PrEP) denotes an effective strategy to reduce the risk of HIV infection. However, many individuals encounter difficulties adhering to the once-daily regimen, which highlights the need for a broader portfolio of PrEP options. The novel HIV capsid inhibitor lenacapavir (LEN), when injected every six month, has shown potential in the recently completed clinical trials. However, clinical...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c205811c-6718-5b23-ac8a-b64e3b5bec33
DOI: 10.1101/2025.08.26.25334527

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIVDOI 10.1101/2025.08.26.25334527Read

Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisSemantic proximity Read

Low clinical impact of HIV drug resistance mutations in oral pre-exposure prophylaxis: a systematic review and meta-analysis.Semantic proximity Read

Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid InhibitorSemantic proximity Read

Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessationSemantic proximity Read

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read

Oral Pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populationsSemantic proximity Read

Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022.Semantic proximity Read

Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemesSemantic proximity Read

A Darwinian model for the evolution of drug resistance to long-acting PrEP during an early HIV infection.Semantic proximity Read

Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.Semantic proximity Read

Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir.Semantic proximity Read

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.Semantic proximity Read